Editor's Note
The Wall Street Journal reports that GW Pharmaceuticals' Epidiolex will cost $32,500 a year and that the company set the price to be in line with other brand-name epilepsy drugs. The company estimates that out-of-pocket costs could range from $5 to $10 a month for those in state Medicaid programs to as high as $200 a month for some private insurance plans.
GW Pharmaceuticals said it plans to charge about $32,500 per patient annually in the U.S. for its new treatment for rare forms of epilepsy, the first prescription drug derived from the marijuana plant.

The U.S. Food and Drug Administration approved Epidiolex, also known as cannabidiol, in June to reduce seizures associated with forms of epilepsy known as Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older.

GW Pharmaceuticals, based in the U.K., makes cannabidiol from a proprietary strain of cannabis designed to maximize a therapeutic component while minimizing components that produce euphoria or a high.